Session Name: Keeping Hearts Healthy - Preventive Treatment in Familial Hypercholesterolemia

Time: Due June 30th, 2025

We appreciate your time and effort in participating in this CME Sessional Evaluation. This evaluation is a pipeline to bring your voice to the leadership, instructors, and CME team. We value your voice and try our best to improve the quality of future activities.

*
*
Did/Will you use this information for specific patient(s)?
What patient/health care problem recently challenged you, and you wish you knew more about?
Comments and Feedback on the learning experience, content, procedure, and instructors, etc. in this session.
As a result of my participation in this activity, I am better able to... 4 - Strongly Agree 3- Agree 2 - Somewhat Disagree 1- Strongly disagree
1234
With a comprehensive knowledge base of familial hypercholesterolemia (FH), including its basic pathophysiology, genetic basis, and natural history, explain why FH is the primary indication for statin treatment in children.
Provide comprehensive patient and family counseling based on the evidence on the effectiveness of statin therapy initiated in childhood for familial hypercholesterolemia (FH)
Incorporate knowledge of statin therapy's safety profile when prescribing statin therapy for the pediatric patient.
The following speaker(s) demonstrated experiential knowledge of the topic 4 - Strongly Agree 3- Agree 2 - Somewhat Disagree 1- Strongly Disagree
1234
Daniel Beacher, MD
Choose the option that best fits your evaluation of this activity: 4 - Strongly Agree 3- Agree 2 - Somewhat Disagree 1- Strongly Disagree
1234
The content provided a fair and balanced coverage of the topic
The content was free of commercial bias
This training was valuable to my practice
I recommend this professional development activity to others